The company's Verafeye platform was designed to provide imaging guidance during cardiac procedures using advanced catheter sensors and deep learning. 

The doctor allegedly targeted some patients more than ten times, treating them again and again with procedures that were not medically necessary. 

Prosecutors successfully argued that the patient would not have died if clinicians had ordered a routine CT exam. 

The health system allegedly ended an ongoing contract with little notice, leaving clinicians and patients without the services of a cardiovascular surgery program. 

The funds are expected to go toward bringing in new employees and accelerating the development of a new cardiac imaging offering. 

According to Ajax Health CEO and industry veteran Duke Rohlen, the new company will be focused on offerings that "prioritize precision, simplicity and efficiency."

The alleged scheme involved a series of diagnostic procedures that, according to the U.S. government, were not medically necessary. 

Medtronic confirmed its decision in a statement, but did not provide any specific details. The deal was originally announced in May.